Gastroenterology
Volume 138, Issue 1 , Pages 34-36 , January 2010

Do Differences in Pegylation of Interferon Alfa Matter?

  • Stefan Zeuzem

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Stefan Zeuzem, MD, Department of Medicine 1, J.W. Goethe University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt A.M., Germany

References 

  1. Harris JM, Martin NE, Modi M. Pegylation (A novel process for modifying pharmacokinetics). Clin Pharmacokinet. 2001;40:539–551
  2. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23(Suppl 1):23–28
  3. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology. 2001;120:1438–1447
  4. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 2002;35:930–936
  5. Formann E, Jessner W, Bennett L, et al. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat. 2003;10:271–276
  6. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol. 2006;45:204–213
  7. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther. 2004;9:491–497
  8. Di Bisceglie AM, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007;14:721–729
  9. McHutchison JG, Lawitz EJ, Shiffman ML, et al. IDEAL Study Team Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593Erratum in: N Engl J Med 2009;361:1027
  10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  12. Rumi M, Aghemo A, Prati GM, et al. Randomized study of peginterferon-α2a plus ribavirin versus peginterferon-α2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138:108–115
  13. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alpha-2a plus ribavirin is more effective than peginterferon alpha-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010;138:116–122
  14. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46:37–47
  15. Awad T, Thorlund K, Hauser G, et al. Cochrane Hepato-Biliary Group Peginterferon alpha-2a may achieve higher sustained virological response than peginterferon alpha-2b in chronic hepatitis C: a Cochrane systematic review of randomized clinical trials. Hepatology. 2009;50(Suppl):707-708A
  16. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis. 2009;48:313–320

 Conflicts of interest The author discloses the following: Clinical investigator, consultant and member of speaker's bureau for Human Genome Sciences, Novartis, Roche, and Schering-Plough.

PII: S0016-5085(09)02051-4

doi: 10.1053/j.gastro.2009.11.034

Gastroenterology
Volume 138, Issue 1 , Pages 34-36 , January 2010

Article Tools